Author details

Full Name

Gerburg M Wulf

Affiliation

ORCID

Career Start Year

1987

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37916958	Allosteric PI3KÎ± Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.	Cancer Discov	2024
36914658	Polymerase Î¸ inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer.	Nat Commun	2023
37992259	Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic <i>BRCA1</i>/<i>2</i>, Germline <i>PALB2</i>, or Homologous Recombination Deficiency Signature.	JCO Precis Oncol	2023
36711754	Reciprocal inhibition of PIN1 and APC/C<sub>CDH1</sub> controls timely G1/S transition and creates therapeutic vulnerability.	Res Sq	2023
36889065	Toker Cell Hyperplasia in the Nipple-Areolar Complex of Transmasculine Individuals.	Mod Pathol	2023
37423299	Simultaneous isolation of hormone receptor-positive breast cancer organoids and fibroblasts reveals stroma-mediated resistance mechanisms.		2023
35347575	The association of infectious mononucleosis and invasive breast cancer in The Health of Women (HOW) Study.		2022
36048535	Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.	Clin Cancer Res	2022
36223740	PARP-inhibition reprograms macrophages toward an anti-tumor phenotype.	Cell Rep	2022
36075133	A <sup>13</sup>C/<sup>31</sup>P surface coil to visualize metabolism and energetics in the rodent brain at 3 Tesla.	J Magn Reson	2022
36068244	STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer.	npj Breast Cancer	2022
36252998	Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer.	J Immunother Cancer	2022
36619972	Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach.	iScience	2022
35149538	Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.	Clin Cancer Res	2022
34994617	Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.	JCO Precis Oncol	2021
33691103	Blockade of 6-phosphogluconate dehydrogenase generates CD8 effector TÂ cells with enhanced anti-tumor function.	Cell Reports	2021
34086382	Visualizing the effects of lactate dehydrogenase (LDH) inhibition and LDH-A genetic ablation in breast and lung cancer with hyperpolarized pyruvate NMR.	NMR in Biomedicine	2021
32939016	Testosterone therapy and breast histopathological features in transgender individuals.	Modern Pathology	2021
34907909	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models.	Journal of Clinical Investigation	2021
34388391	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.	Cell	2021
34548479	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.	Nat Commun	2021
32616507	Not Black or White but Shades of Gray: Homologous Recombination Deficiency as a Continuous Variable Modulated by RNF168.	Cancer Research	2020
31745703	Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.	J Cancer Res Clin Oncol	2020
32193458	Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer.	Nat Commun	2020
32193285	Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition.	Cancer Res	2020
32164626	An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.	BMC Cancer	2020
32880602	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.	JAMA Oncol	2020
32923889	Response of Brain Metastases From <i>PIK3CA</i>-Mutant Breast Cancer to Alpelisib.	JCO Precis Oncol	2020
32513774	The INPP4B Tumor Suppressor Modulates EGFR Trafficking and Promotes Triple-Negative Breast Cancer.	Cancer Discov	2020
33119476	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.	J Clin Oncol	2020
30880072	Olaparib and Î±-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.	Lancet Oncol	2019
31750394	Establishing a Cohort of Transgender Men and Gender Nonconforming Individuals to Understand the Molecular Impact of Testosterone on Breast Physiology.		2019
30527351	Interdisciplinary Management of Transgender Individuals at Risk for Breast Cancer: Case Reports and Review of the Literature.	Clinical Breast Cancer	2019
31015319	PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.	Cancer Discov	2019
31213465	Chromosome 12p Amplification in Triple-Negative/<i>BRCA1-</i>Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity.	Cancer Res	2019
31061439	How cancers usurp macrophages to keep growing.	Cell Research	2019
31315128	Efficient Human Cytomegalovirus Replication in Primary Endothelial Cells Is SOCS3 Dependent.	Intervirology	2019
31194225	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.	JAMA Oncol	2019
29203461	Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer.	Cancer Discov	2018
30505804	Editorial: EBV-Associated Carcinomas: Presence, Role, and Prevention Strategies.	Frontiers in Oncology	2018
29924804	Reporters to mark and eliminate basal or luminal epithelial cells in culture and in vivo.	PLoS Biol	2018
27993796	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.	Ann Oncol	2017
29109428	Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland.	Scientific Reports	2017
27573169	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.	Clin Cancer Res	2017
28247034	Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer.	J Cancer Res Clin Oncol	2017
27313209	Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system.	Proceedings of the National Academy of Sciences of the United States of America	2016
27333046	Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation.	EBioMedicine	2016
26824656	Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton.	Cell	2016
27402769	Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.	Proc Natl Acad Sci U S A	2016
25818297	The Rab2A GTPase promotes breast cancer stem cells and tumorigenesis via Erk signaling activation.	Cell Rep	2015